Safety-Related Labeling Changes
In the post‑marketing setting, cases of skeletal abnormalities, and neonatal death have been reported in pregnant women receiving trastuzumab.
Trade Name
Kanjinti
Updated Section
4.6 Fertility, pregnancy and lactation
Month
Mar,2023